Clinical Commander

Back to dossier
uro.bph.v1PRODUCTION
uro.bph.v1

Benign Prostatic Hyperplasia (BPH) — chronic LUTS in adult men

urologychronicadultgeriatric
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Adult man with LUTS (storage + voiding) — chronic BPH differential. Explicit pivots: acute prostatitis (fever + tender DRE) → uro.prostatitis.v1; prostate cancer (DRE nodule, elevated PSA velocity) → urology referral; female LUTS → out of scope (AUA BPH 2021)

Inputs
1
Actions
0
Advance rule
Set
Advance when

engine scope confirmed

Patient inputs (20)

BPH prevalence rises with age; PSA screening window is 55–69 per USPSTF (shared decision-making); surgical risk increases with age

Anticholinergics + decongestants (pseudoephedrine) + opioids worsen LUTS; diuretics drive nocturia; α-blocker + tadalafil hypotension caution; cataract pending → IFIS flag (AUA BPH 2021)

Pending cataract surgery + α-blocker → IFIS risk; document for ophthalmologist; tamsulosin highest risk (AUA BPH 2021)

Engine scope is adult men; female LUTS routed to overactive-bladder / interstitial-cystitis engines (out of scope)

Digital rectal exam — size estimation (small <30 cc / medium 30–80 / large >80) + nodule check (firm asymmetric → cancer workup) (AUA BPH 2021)

Bladder ultrasound PVR — high (>250 mL) increases retention risk + antimuscarinic caution; gates AUR risk (AUA BPH 2021)

Rule UTI / hematuria; persistent hematuria → AUA 2020 microhematuria workup before attribution to BPH (AUA BPH 2021)

Baseline renal function; obstructive uropathy workup if elevated; dose adjustment for some medications (AUA BPH 2021)

International Prostate Symptom Score (0–35) — severity band drives initial therapy intensity (≤7 mild, 8–19 moderate, ≥20 severe) (AUA BPH 2021)

IPSS bother / quality-of-life question (0–6) gates whether to escalate; not all moderate IPSS bother the patient (AUA BPH 2021)

Baseline BP — orthostatic / supine for α-blocker initiation; uroselective preferred if low baseline (AUA BPH 2021)

Optional — Qmax <10 mL/s favors obstruction; not routinely required for initial therapy but valuable before surgery (AUA BPH 2021)

Concurrent ED + LUTS → tadalafil 5 mg daily dual indication (FDA approved) (AUA BPH 2021)

Concurrent HTN → consider doxazosin / terazosin (also lower BP) vs uroselective tamsulosin / silodosin / alfuzosin (minimal BP effect) (AUA BPH 2021)

Postural hypotension or fall history → uroselective α-blocker preferred; titrate cautiously (AUA BPH 2021)

Family hx prostate cancer (especially first-degree, BRCA) → earlier PSA + urology shared decision-making (USPSTF)

Prior catheter / instrumentation → urethral stricture differential; cystoscopy may be warranted (EAU BPH 2015)

Breakthrough on max combination 6–12 mo → refractory phenotype → urology referral for surgical evaluation (AUA BPH 2021)

Prostate volume estimate (TRUS or MRI) — gates 5-ARI eligibility (>40 cc) and surgical option (TURP ≤80 g, HoLEP / open >80 g) (AUA BPH 2021)

Counseled per USPSTF age 55–69 shared decision-making; elevated PSA → urology referral; BPH typically PSA <4 unless large gland; 5-ARI halves PSA — double measured value for screening (AUA BPH 2021)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (13)

13 need judgement
  • informationallife_threateninghydronephrosis_renal_failure
    Bilateral hydronephrosis + obstructive AKI — STAT urology + decompression (Foley vs PCN); admit (AUA BPH 2021; KDIGO AKI 2026)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresevere_IPSS_ge_20
    Severe LUTS (IPSS ≥20) with high bother — combination α-blocker + 5-ARI if prostate >40 cc; consider surgical evaluation (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereacute_urinary_retention
    AUR with palpable bladder + suprapubic pain + inability to void — STAT Foley + α-blocker + TWOC at 24–72 h (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererefractory_to_medical
    Breakthrough on max combination therapy at 6–12 mo — urology referral for surgical evaluation (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepostop_bleeding
    Post-TURP / open prostatectomy bleeding — CBI; transfusion if Hb threshold; cystoscopy + clot evacuation if persistent (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemoderate_IPSS_8_19
    Moderate LUTS (IPSS 8–19) with bother — α-blocker first-line medical therapy (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_uti_secondary_to_bph
    Recurrent UTI in adult man with BPH — workup PVR + obstruction; urology referral; consider surgical relief (AUA BPH 2021; IDSA 2010)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatebladder_stone_complication
    Bladder stone secondary to BPH incomplete emptying — endoscopic stone removal + concurrent BPH surgery (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatehematuria_workup_bph
    Hematuria in BPH patient — MUST exclude urothelial malignancy per AUA 2020 microhematuria workup before attribution (AUA 2020 PMID 32698717)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderate5alpha_reductase_eligible
    Prostate >40 cc + bothersome moderate-severe LUTS — 5α-reductase inhibitor eligible; 6 mo onset; doubles measured PSA (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildmild_lower_urinary_tract_sx_IPSS_le7
    Mild LUTS (IPSS ≤7) with minimal bother — lifestyle modification + watchful waiting; no medication (AUA BPH 2021 PMID 34384237)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildpostop_stress_incontinence
    Post-TURP stress incontinence persistent beyond 3–6 mo — Kegel PT; delayed surgical sling / AUS referral (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildpostop_dry_orgasm_alpha_blocker
    Retrograde ejaculation on silodosin / tamsulosin OR post-TURP (expected ~70%) — counsel; switch to alfuzosin if undesired (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

BPH — AUA 2021 ladder: lifestyle → α-blocker → 5-ARI / combo → PDE5i overlay → antimuscarinic for storage → surgery for refractory
axis: bph_medical_and_surgical_ladderstep 1 - Mild LUTS (IPSS ≤7) — lifestyle + watchful waiting
Selected step "Mild LUTS (IPSS ≤7) — lifestyle + watchful waiting" — IPSS ≤7 OR minimal bother regardless of IPSS
  • Lifestyle modification — fluid timing, caffeine / EtOH reduction, avoid OTC anticholinergics / decongestants
    first line
    lifestyle
    triggers: mild_LUTS, minimal_bother
    AUA BPH 2021 — first-line for mild symptoms; no medication exposure (PMID 34384237)

outpatient playbook — drug actions (6)

  1. 1. tamsulosin (α1A uroselective first-line)
    0.4 mg PO daily • PO • once daily
    trigger: IPSS ≥8 with bother, no contraindication, no pending cataract (or counselled)
    AUA BPH 2021 first-line; minimal BP effect; IFIS counsel pre-cataract (PMID 34384237)
  2. 2. alfuzosin / silodosin (uroselective alternatives)
    Alfuzosin 10 mg or silodosin 8 mg PO daily • PO • once daily with meal
    trigger: Tamsulosin intolerance or ejaculatory function priority (alfuzosin lowest)
    AUA BPH 2021 uroselective alternatives
  3. 3. doxazosin / terazosin (HTN overlay)
    Doxazosin 1→8 mg or terazosin 1→10 mg PO at bedtime, titrated • PO • once daily titrated
    trigger: Concurrent HTN; cost-driven preference
    AUA BPH 2021 — α-blocker with HTN benefit; orthostatic caution (MTOPS PMID 14681504)
  4. 4. finasteride or dutasteride (5-ARI add-on)
    Finasteride 5 mg or dutasteride 0.5 mg PO daily • PO • once daily
    trigger: Prostate >40 cc + breakthrough on α-blocker monotherapy
    AUA BPH 2021 + MTOPS / CombAT — combination superior for large gland + moderate-severe (PMID 14681504; PMID 19825505)
  5. 5. tadalafil (PDE5i overlay)
    5 mg PO daily • PO • once daily
    trigger: Concurrent ED + LUTS dual indication
    FDA approved dual indication; α-blocker hypotension caution
  6. 6. antimuscarinic / β3 (storage overlay)
    Solifenacin 5–10 mg OR mirabegron 25–50 mg PO daily • PO • once daily
    trigger: Storage-predominant + PVR <250 mL + no retention history
    AUA BPH 2021 — storage symptom relief; β3 lower retention risk

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Frequency / urgency / nocturia (storage) ± urge incontinence in adult man (AUA BPH 2021 PMID 34384237); Weak stream / hesitancy / intermittency / incomplete emptying / straining (voiding) in adult man (AUA BPH 2021); Inability to void + palpable bladder + suprapubic pain — AUR (STAT decompression).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Benign Prostatic Hyperplasia (BPH) — chronic LUTS in adult men** (uro.bph.v1).
Phenotype framing: BPH vs prostate cancer (DRE nodule, elevated PSA velocity) vs prostatitis (fever + tender DRE) vs urethral stricture (history of instrumentation / STI) vs neurogenic bladder (CVA, DM, MS, cord injury) vs overactive bladder (storage-predominant without obstruction) vs polyuria (DI, DM, CHF diuresis) vs urethral cancer (AUA BPH 2021)
Scope: Adult man with LUTS (storage + voiding) — chronic BPH differential. Explicit pivots: acute prostatitis (fever + tender DRE) → uro.prostatitis.v1; prostate cancer (DRE nodule, elevated PSA velocity) → urology referral; female LUTS → out of scope (AUA BPH 2021)

No severity triggers fired against current inputs.

Plan

Regimen axis: **BPH — AUA 2021 ladder: lifestyle → α-blocker → 5-ARI / combo → PDE5i overlay → antimuscarinic for storage → surgery for refractory** — step "Mild LUTS (IPSS ≤7) — lifestyle + watchful waiting".
1. Lifestyle modification — fluid timing, caffeine / EtOH reduction, avoid OTC anticholinergics / decongestants (lifestyle, first line) — AUA BPH 2021 — first-line for mild symptoms; no medication exposure (PMID 34384237)

Setting playbook (outpatient) — Primary BPH pathway: IPSS + DRE + UA + PSA + creatinine + PVR; initiate α-blocker for moderate-severe; counsel medications + IFIS (cataract pre-op); 6–12 wk re-check; add 5-ARI if prostate >40 cc; combination if breakthrough; refer urology for complicated (AUA BPH 2021)
2. tamsulosin (α1A uroselective first-line) 0.4 mg PO daily PO once daily — IPSS ≥8 with bother, no contraindication, no pending cataract (or counselled) (AUA BPH 2021 first-line; minimal BP effect; IFIS counsel pre-cataract (PMID 34384237))
3. alfuzosin / silodosin (uroselective alternatives) Alfuzosin 10 mg or silodosin 8 mg PO daily PO once daily with meal — Tamsulosin intolerance or ejaculatory function priority (alfuzosin lowest) (AUA BPH 2021 uroselective alternatives)
4. doxazosin / terazosin (HTN overlay) Doxazosin 1→8 mg or terazosin 1→10 mg PO at bedtime, titrated PO once daily titrated — Concurrent HTN; cost-driven preference (AUA BPH 2021 — α-blocker with HTN benefit; orthostatic caution (MTOPS PMID 14681504))
5. finasteride or dutasteride (5-ARI add-on) Finasteride 5 mg or dutasteride 0.5 mg PO daily PO once daily — Prostate >40 cc + breakthrough on α-blocker monotherapy (AUA BPH 2021 + MTOPS / CombAT — combination superior for large gland + moderate-severe (PMID 14681504; PMID 19825505))
6. tadalafil (PDE5i overlay) 5 mg PO daily PO once daily — Concurrent ED + LUTS dual indication (FDA approved dual indication; α-blocker hypotension caution)
7. antimuscarinic / β3 (storage overlay) Solifenacin 5–10 mg OR mirabegron 25–50 mg PO daily PO once daily — Storage-predominant + PVR <250 mL + no retention history (AUA BPH 2021 — storage symptom relief; β3 lower retention risk)

Non-pharmacologic actions:
- Patient education — IPSS expectations, medication onset (α-blocker days, 5-ARI 6 mo), IFIS pre-cataract counsel
- Cataract surgery flag in chart — alert ophthalmologist of α-blocker history
- Bladder diary at home for re-check (AUA BPH 2021)
- 6–12 wk follow-up to assess response + side effects
- Annual DRE + PSA per USPSTF shared decision (USPSTF)
- Urology referral for: refractory on combination 6–12 mo, recurrent UTI, bladder stones, hydronephrosis, AUR, suspected prostate cancer (AUA BPH 2021)

AVOID / contraindication checks:
- Tamsulosin_silodosin_IFIS_intraoperative_floppy_iris_syndrome_cataract_surgery (AUA BPH 2021 PMID 34384237)
- Tamsulosin_IFIS_persists_even_after_discontinuation_durable_iris_atrophy (FDA)
- Alpha_blocker_orthostatic_hypotension_first_dose_phenomenon_bedtime_titration (AUA BPH 2021)
- Doxazosin_terazosin_higher_orthostasis_than_uroselective_avoid_in_falls (AUA BPH 2021)
- Silodosin_avoid_if_eGFR_lt_30_ChildPugh_C (FDA)
- Silodosin_28pct_retrograde_ejaculation (AUA BPH 2021)
- Finasteride_dutasteride_PFS_post_finasteride_syndrome_sexual_mood_persistent (FDA Black Box)
- Finasteride_dutasteride_double_PSA_for_screening_interpretation (AUA BPH 2021)
- Finasteride_dutasteride_teratogenic_avoid_handling_crushed_in_pregnancy (FDA Pregnancy_X)
- Finasteride_dutasteride_possible_high_grade_prostate_cancer_increase_PCPT_REDUCE (FDA)
- Tadalafil_with_nitrates_severe_hypotension_contraindicated (FDA)
- Tadalafil_with_alpha_blocker_additive_hypotension_caution (FDA)
- Antimuscarinic_avoid_if_PVR_gt_250mL_retention_risk (AUA BPH 2021)
- Antimuscarinic_oxybutynin_CNS_anticholinergic_dementia_in_elderly_use_ER_or_alternative (AGS_Beers)
- Mirabegron_HTN_BP_monitoring_first_weeks (FDA)
- AUR_slow_decompression_clamp_500mL_avoid_hematuria_ex_vacuo (AUA BPH 2021)
- Hematuria_in_BPH_MUST_exclude_urothelial_malignancy_AUA_2020_workup (AUA 2020 PMID 32698717)

Monitoring

Regimen monitoring:
- IPSS re score q3 to 6mo on therapy (AUA BPH 2021)
- PSA q12mo baseline then with 5ARI double measured value (AUA BPH 2021)
- BMP q6 to 12mo for obstructive nephropathy screen (AUA BPH 2021)
- PVR if symptoms worsen or AUR episode (AUA BPH 2021)
- orthostatic BP after alpha blocker initiation or dose increase (AUA BPH 2021)
- 5ARI sexual side effect review at 3 and 6mo (FDA)
- pre cataract surgery document alpha blocker history for ophthalmologist (AUA BPH 2021)
- uroflowmetry baseline if surgical evaluation planned (AUA BPH 2021)
- annual DRE for prostate cancer screen per USPSTF shared decision (USPSTF)

Setting (outpatient) monitoring:
- IPSS re-score at 6–12 wk on therapy (AUA BPH 2021)
- Orthostatic BP after α-blocker initiation (AUA BPH 2021)
- PSA q12 mo + DRE annually if on 5-ARI (double measured PSA for screening) (AUA BPH 2021)
- BMP q6–12 mo for obstructive nephropathy screen (AUA BPH 2021)
- PVR if symptoms worsen or AUR episode (AUA BPH 2021)
- 5-ARI sexual / mood side effects review at 3 + 6 mo (FDA)

Follow-up plan: Annual IPSS + DRE; surgical referral if breakthrough on combination after 6–12 mo; counsel lifelong trajectory + IFIS (cataract surgery interaction) + retrograde ejaculation expectation + 5-ARI sexual / mood effects (AUA BPH 2021)
- Close-out criterion: follow-up + counselling complete

Monitoring phase: IPSS re-score q3–6 mo on therapy; PSA q12 mo if on 5-ARI (double measured value for screening interpretation); BMP q6–12 mo; PVR if symptoms worsen; uroflowmetry if surgical evaluation (AUA BPH 2021)

Disposition

Current setting: outpatient — Primary BPH pathway: IPSS + DRE + UA + PSA + creatinine + PVR; initiate α-blocker for moderate-severe; counsel medications + IFIS (cataract pre-op); 6–12 wk re-check; add 5-ARI if prostate >40 cc; combination if breakthrough; refer urology for complicated (AUA BPH 2021)

Disposition criteria:
- Outpatient continuation if response + tolerance
- Urology referral for complicated / refractory / surgical
- ED if AUR / hematuria with clots / sepsis appearance

Escalation triggers (move to higher acuity):
- Refractory on max combination at 6–12 mo → urology referral for surgical evaluation (AUA BPH 2021)
- Recurrent UTI in adult man → urology + complicated UTI workup overlap (uro.uti.complicated.v1)
- Hematuria persisting on UA → AUA 2020 microhematuria workup (route to symptom.hematuria.v1)
- AUR / hydronephrosis / obstructive AKI → ED + admit
- DRE nodule + elevated PSA velocity → urology + biopsy (prostate cancer pivot)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Bilateral hydronephrosis + obstructive AKI — STAT urology + decompression (Foley vs PCN); admit (AUA BPH 2021; KDIGO AKI 2026)
- [SEVERE] Severe LUTS (IPSS ≥20) with high bother — combination α-blocker + 5-ARI if prostate >40 cc; consider surgical evaluation (AUA BPH 2021)
- [SEVERE] AUR with palpable bladder + suprapubic pain + inability to void — STAT Foley + α-blocker + TWOC at 24–72 h (AUA BPH 2021)

Citations

- AUA BPH 2021 Parts I/II + AUA BPH 2023 amendment + MTOPS NEJM 2003 (McConnell/Lepor combination superiority) + CombAT 4-year (dutasteride + tamsulosin) + EAU non-neurogenic male LUTS/BPO 2015 + UroLift L.I.F.T. (minimally invasive) + USPSTF PSA screening 55-69 shared decision [PMID:34384237](https://pubmed.ncbi.nlm.nih.gov/34384237/)
- Cited evidence (PMID 34384236) [PMID:34384236](https://pubmed.ncbi.nlm.nih.gov/34384236/)
- Cited evidence (PMID 37706750) [PMID:37706750](https://pubmed.ncbi.nlm.nih.gov/37706750/)
- Cited evidence (PMID 14681504) [PMID:14681504](https://pubmed.ncbi.nlm.nih.gov/14681504/)
- Cited evidence (PMID 19825505) [PMID:19825505](https://pubmed.ncbi.nlm.nih.gov/19825505/)

Last reconciled with current guidelines: 2026-05-22.
References
  • AUA BPH 2021 Parts I/II + AUA BPH 2023 amendment + MTOPS NEJM 2003 (McConnell/Lepor combination superiority) + CombAT 4-year (dutasteride + tamsulosin) + EAU non-neurogenic male LUTS/BPO 2015 + UroLift L.I.F.T. (minimally invasive) + USPSTF PSA screening 55-69 shared decision — PMID:34384237
  • Cited evidence (PMID 34384236) — PMID:34384236
  • Cited evidence (PMID 37706750) — PMID:37706750
  • Cited evidence (PMID 14681504) — PMID:14681504
  • Cited evidence (PMID 19825505) — PMID:19825505